SHANGHAI , April 8, 2024 /PRNewswire/ -- 9 April 2024 (Beijing Time) , Abbisko Therapeutics Co., Ltd. (Abbisko Therapeutics) announced the completion of patient enrollment for its pivotal Phase III trial, MANEUVER (ABSK021-301) ...
Dosing of first patient completed in Cohort 2 following Data Monitoring Committee approval to proceed Encouraging safety, tolerability and early pharmacodynamic changes observed in Cohort 1 with lead program VTX-801 PARIS , April ...
The world's first non-surgical cervical HSIL treatment validated by an international Phase III clinical study with proven efficacy; The response rate increased by 89.4% compared to the placebo control group, with a low incidence of adverse ...
SHENZHEN, China , March 18, 2024 /PRNewswire/ -- On March 18 2024, Shenzhen chipscreen biosciences Co., Ltd. (hereinafter referred to as "chipscreen biosciences", stock code: 688321. SH) announced that the Phase II clinical trial ...
Partnership with leading US-based ALS patient advocacy group furthers myTomorrows' mission of ensuring that patients confronting life-threatening diseases are aware of all possible treatment options NEW YORK , March 14, 2024 ...
Data presented by the MS team at Hadassah Medical Center, Jerusalem , led by Prof. Dimitrios Karussis, in the Americas Committee for Treatment and Research in Multiple Sclerosis Forum reveal consistent reductions in serum levels of both NfL ...
WUXI, China , Feb. 25, 2024 /PRNewswire/ -- BioCity Biopharma is pleased to announce the completion of enrollment of all 120 participants in the IgA nephropathy (IgAN) cohort in a randomized, double-blind, placebo-controlled Phase 2 ...
WUHAN, China , Feb. 5, 2024 /PRNewswire/ -- iRegene Therapeutics Co., Ltd (iRegene) recently announced that NouvNeu001, the company's first innovative product, has completed the dosing for its first patient at Beijing Hospital, and the ...
CHENGDU, China , Feb. 5, 2024 /PRNewswire/ -- Technoderma Medicines, Inc. ("the Company"), a clinical stage biopharmaceutical company, is pleased to report that the Company has completed its Phase 2a clinical trial (NCT05802173) of ...
Rancho Santa Margarita, Calif., Feb. 05, 2024 (GLOBE NEWSWIRE) -- Blue California , an industry leader in science-driven ingredient development, announced the successful completion of a groundbreaking human clinical trial of ergothioneine. A ...
Bharat Biotech, in collaboration with Biofabri, a Spanish biopharmaceutical firm, is conducting trials for the first live attenuated vaccine MTBVAC ( ) derived from a human strain of Mycobacterium tuberculosis. These trials aim to assess the safety and ...
A multisite clinical trial offers promising outcomes for patients with metastatic and recurrent uterine cancer, also known as endometrial cancer. Presented at the annual meeting of the Society of Gynecologic Oncologists, the study compiled data from ...
Researchers at the University of Oxford in the UK have initiated the first human clinical trial to evaluate ChAdOx1 NipahB vaccine designed to safeguard individuals against the deadly Nipah virus . ( ) ChAdOx1 NipahB Vaccine Trial with 51 Participants to Combat Nipah Virus Threat Fifty-one people aged 18 to 55 will participate in the ...
The stromal processing peptidase (SPP), a chloroplast plant enzyme, reduces the clumping of proteins that cause the pathogenic alterations in models of Huntingtons disease in human cells and the nematode Caenorhabditis elegans ( ). ...
A group of US researchers, who first conducted an ‘ artificial womb ’ experiment in lamb, are now seeking Food and Drug Administration (FDA) approval for its tests on humans ( ). This could potentially reduce deaths and disability for babies ...
Subscribe to our Free Newsletters!
Disclaimer - All information and content on this site are for information and educational purposes only. The information should not be used for either diagnosis or treatment or both for any health related problem or disease. Always seek the advice of a qualified physician for medical diagnosis and treatment.
Full Disclaimer
Advertise with us | Medindia Copyright | Privacy Policy | Terms of Use © All Rights Reserved 1997 - 2024
Careers